Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients.

Lefaucheur C, Viglietti D, Bouatou Y, Philippe A, Pievani D, Aubert O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Loupy A, Halloran PF, Dragun D.

Kidney Int. 2019 Jul;96(1):189-201. doi: 10.1016/j.kint.2019.01.030. Epub 2019 Mar 15.

PMID:
31005275
2.

Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression.

Snanoudj R, Kamar N, Cassuto E, Caillard S, Metzger M, Merville P, Thierry A, Jollet I, Grimbert P, Anglicheau D, Hazzan M, Choukroun G, Hurault De Ligny B, Janbon B, Vuiblet V, Devys A, Le Meur Y, Delahousse M, Morelon E, Bailly E, Girerd S, Amokrane K, Legendre C, Hertig A, Rondeau E, Taupin JL.

Kidney Int. 2019 Jun;95(6):1471-1485. doi: 10.1016/j.kint.2018.12.029. Epub 2019 Mar 5.

PMID:
30955869
3.

Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens.

Delville M, Lamarthée B, Pagie S, See SB, Rabant M, Burger C, Gatault P, Giral M, Thaunat O, Arzouk N, Hertig A, Hazzan M, Matignon M, Mariat C, Caillard S, Kamar N, Sayegh J, Westeel PF, Garrouste C, Ladrière M, Vuiblet V, Rivalan J, Merville P, Bertrand D, Le Moine A, Van Huyen JPD, Cesbron A, Cagnard N, Alibeu O, Satchell SC, Legendre C, Zorn E, Taupin JL, Charreau B, Anglicheau D.

J Am Soc Nephrol. 2019 Apr;30(4):692-709. doi: 10.1681/ASN.2018080868. Epub 2019 Mar 8.

PMID:
30850439
4.

Markers of graft microvascular endothelial injury may identify harmful donor-specific anti-HLA antibodies and predict kidney allograft loss.

Louis K, Hertig A, Taupin JL, Buob D, Jamme M, Brocheriou I, Luque Y, Jouanneau C, Ouali N, Audouin M, Rondeau E, Xu-Dubois YC.

Am J Transplant. 2019 Mar 5. doi: 10.1111/ajt.15340. [Epub ahead of print]

PMID:
30836425
5.

Measuring anti-HLA antibody active concentration and affinity by surface plasmon resonance: Comparison with the luminex single antigen flow beads and T-cell flow cytometry crossmatch results.

Visentin J, Leu DL, Mulder A, Jambon F, Badier L, Lee JH, Guidicelli G, Bouthemy C, Ralazamahaleo M, Claas F, Di Primo C, Taupin JL.

Mol Immunol. 2019 Apr;108:34-44. doi: 10.1016/j.molimm.2019.02.006. Epub 2019 Feb 16.

PMID:
30776727
6.

Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection.

Bouatou Y, Viglietti D, Pievani D, Louis K, Duong Van Huyen JP, Rabant M, Aubert O, Taupin JL, Glotz D, Legendre C, Loupy A, Lefaucheur C.

Am J Transplant. 2019 Jul;19(7):1972-1988. doi: 10.1111/ajt.15299. Epub 2019 Mar 15.

PMID:
30748089
7.

Baseline graft status is a critical predictor of kidney graft failure after diarrhoea.

Devresse A, Morin L, Aulagnon F, Taupin JL, Scemla A, Lanternier F, Aubert O, Aidoud AA, Lebreton X, Sberro-Soussan R, Snanoudj R, Amrouche L, Tinel C, Martinez F, Bererhi L, Anglicheau D, Lortholary O, Legendre C, Avettand-Fenoel V, Zuber J.

Nephrol Dial Transplant. 2019 Jan 3. doi: 10.1093/ndt/gfy386. [Epub ahead of print]

PMID:
30608553
8.

Correction: Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 Jul 27;15(7):e1002637. doi: 10.1371/journal.pmed.1002637. eCollection 2018 Jul.

9.

Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.

Brugière O, Roux A, Le Pavec J, Sroussi D, Parquin F, Pradère P, Dupin C, Bunel V, Mourin G, Jebrak G, Dauriat G, Castier Y, Mordant P, Lortat-Jacob B, Jean-Baptiste S, Mal H, Suberbielle C, Gautreau C, Caillat-Zucman S, Cazes A, Thabut G, Taupin JL.

Eur Respir J. 2018 Aug 23;52(2). pii: 1701898. doi: 10.1183/13993003.01898-2017. Print 2018 Aug.

PMID:
29976654
10.

Banff Lung Report: Current knowledge and future research perspectives for diagnosis and treatment of pulmonary antibody-mediated rejection (AMR).

Roux A, Levine DJ, Zeevi A, Hachem R, Halloran K, Halloran PF, Gibault L, Taupin JL, Neil DAH, Loupy A, Adam BA, Mengel M, Hwang DM, Calabrese F, Berry G, Pavlisko EN.

Am J Transplant. 2019 Jan;19(1):21-31. doi: 10.1111/ajt.14990. Epub 2018 Aug 1.

PMID:
29956477
11.

Overcoming non-specific binding to measure the active concentration and kinetics of serum anti-HLA antibodies by surface plasmon resonance.

Visentin J, Couzi L, Dromer C, Neau-Cransac M, Guidicelli G, Veniard V, Coniat KN, Merville P, Di Primo C, Taupin JL.

Biosens Bioelectron. 2018 Oct 15;117:191-200. doi: 10.1016/j.bios.2018.06.013. Epub 2018 Jun 7.

PMID:
29902635
12.

The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.

Courant M, Visentin J, Linares G, Dubois V, Lepreux S, Guidicelli G, Thaunat O, Merville P, Couzi L, Taupin JL.

Nephrol Dial Transplant. 2018 Oct 1;33(10):1872. doi: 10.1093/ndt/gfy182. No abstract available.

PMID:
29897514
13.

Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.

Viglietti D, Bouatou Y, Kheav VD, Aubert O, Suberbielle-Boissel C, Glotz D, Legendre C, Taupin JL, Zeevi A, Loupy A, Lefaucheur C.

Kidney Int. 2018 Oct;94(4):773-787. doi: 10.1016/j.kint.2018.03.015. Epub 2018 May 22.

PMID:
29801667
14.

Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.

Bouquegneau A, Loheac C, Aubert O, Bouatou Y, Viglietti D, Empana JP, Ulloa C, Murad MH, Legendre C, Glotz D, Jackson AM, Zeevi A, Schaub S, Taupin JL, Reed EF, Friedewald JJ, Tyan DB, Süsal C, Shapiro R, Woodle ES, Hidalgo LG, O'Leary J, Montgomery RA, Kobashigawa J, Jouven X, Jabre P, Lefaucheur C, Loupy A.

PLoS Med. 2018 May 25;15(5):e1002572. doi: 10.1371/journal.pmed.1002572. eCollection 2018 May. Erratum in: PLoS Med. 2018 Jul 27;15(7):e1002637.

15.

Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients.

Dao M, Habès D, Taupin JL, Mussini C, Redon MJ, Suberbielle C, Jacquemin E, Gonzales E, Guettier C.

Liver Transpl. 2018 Jul;24(7):897-907. doi: 10.1002/lt.25187.

PMID:
29704327
16.

The disappointing contribution of anti-human leukocyte antigen donor-specific antibodies characteristics for predicting allograft loss.

Courant M, Visentin J, Linares G, Dubois V, Lepreux S, Guidicelli G, Thaunat O, Merville P, Couzi L, Taupin JL.

Nephrol Dial Transplant. 2018 Oct 1;33(10):1853-1863. doi: 10.1093/ndt/gfy088.

PMID:
29672702
17.

Prevalence, distribution and amplitude of the complement interference phenomenon in single antigen flow beads assays.

Guidicelli G, Visentin J, Franchini N, Borg C, Merville P, Couzi L, Taupin JL.

HLA. 2018 Jun;91(6):507-513. doi: 10.1111/tan.13263.

PMID:
29604172
18.

Antibody-mediated rejection in pediatric small bowel transplantation: Capillaritis is a major determinant of C4d positivity in intestinal transplant biopsies.

Rabant M, Racapé M, Petit LM, Taupin JL, Aubert O, Bruneau J, Barbet P, Goulet O, Chardot C, Suberbielle C, Lacaille F, Canioni D, Duong Van Huyen JP.

Am J Transplant. 2018 Sep;18(9):2250-2260. doi: 10.1111/ajt.14685. Epub 2018 Mar 24.

PMID:
29397036
19.

Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection.

Viglietti D, Loupy A, Aubert O, Bestard O, Duong Van Huyen JP, Taupin JL, Glotz D, Legendre C, Jouven X, Delahousse M, Kamar N, Lefaucheur C.

J Am Soc Nephrol. 2018 Feb;29(2):606-619. doi: 10.1681/ASN.2017070749. Epub 2017 Dec 18.

20.

Isolated v-lesion in kidney transplant recipients: Characteristics, association with DSA, and histological follow-up.

Rabant M, Boullenger F, Gnemmi V, Pellé G, Glowacki F, Hertig A, Brocheriou I, Suberbielle C, Taupin JL, Anglicheau D, Legendre C, Duong Van Huyen JP, Buob D.

Am J Transplant. 2018 Apr;18(4):972-981. doi: 10.1111/ajt.14617. Epub 2018 Jan 12.

21.

Comments on "Direct quantitative measurement of the kinetics of HLA-specific antibody interactions with isolated HLA proteins".

Di Primo C, Taupin JL, Visentin J.

Hum Immunol. 2018 Feb;79(2):129. doi: 10.1016/j.humimm.2017.11.009. Epub 2017 Nov 22. No abstract available.

PMID:
29175109
22.

Predicted indirectly recognizable HLA epitopes (PIRCHE): Only the tip of the iceberg?

Guidicelli G, Taupin JL, Visentin J.

Am J Transplant. 2018 Feb;18(2):521-522. doi: 10.1111/ajt.14474. Epub 2017 Sep 5. No abstract available.

23.

Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.

Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, Legendre C, Taupin JL, Duong Van-Huyen JP, Loupy A, Lefaucheur C.

Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26.

PMID:
28554738
24.

Conformational Variants of HLA-I Antigens on Luminex Single Antigen Beads.

Visentin J, Guidicelli G, Taupin JL.

Transplantation. 2017 Apr;101(4):e152-e153. doi: 10.1097/TP.0000000000001607. No abstract available.

PMID:
27941435
25.

The emerging role of ECM crosslinking in T cell mobility as a hallmark of immunosenescence in humans.

Moreau JF, Pradeu T, Grignolio A, Nardini C, Castiglione F, Tieri P, Capri M, Salvioli S, Taupin JL, Garagnani P, Franceschi C.

Ageing Res Rev. 2017 May;35:322-335. doi: 10.1016/j.arr.2016.11.005. Epub 2016 Nov 19. Review.

26.

Donor-Specific Anti-HLA Antibodies in Allogeneic Hematopoietic Stem Cell Transplantation.

Morin-Zorman S, Loiseau P, Taupin JL, Caillat-Zucman S.

Front Immunol. 2016 Aug 12;7:307. doi: 10.3389/fimmu.2016.00307. eCollection 2016. Review.

27.

Lung intragraft donor-specific antibodies as a risk factor for graft loss.

Visentin J, Chartier A, Massara L, Linares G, Guidicelli G, Blanchard E, Parrens M, Begueret H, Dromer C, Taupin JL.

J Heart Lung Transplant. 2016 Dec;35(12):1418-1426. doi: 10.1016/j.healun.2016.06.010. Epub 2016 Jun 24.

PMID:
27450460
28.

Reassessment of T Lymphocytes Crossmatches Results Prediction With Luminex Class I Single Antigen Flow Beads Assay.

Visentin J, Bachelet T, Borg C, Franchini N, Nong T, Lee JH, Couzi L, Merville P, Guidicelli G, Taupin JL.

Transplantation. 2017 Mar;101(3):624-630. doi: 10.1097/TP.0000000000001239.

PMID:
27336398
29.

Genome-Wide Association Study of Acute Renal Graft Rejection.

Ghisdal L, Baron C, Lebranchu Y, Viklický O, Konarikova A, Naesens M, Kuypers D, Dinic M, Alamartine E, Touchard G, Antoine T, Essig M, Rerolle JP, Merville P, Taupin JL, Le Meur Y, Grall-Jezequel A, Glowacki F, Noël C, Legendre C, Anglicheau D, Broeders N, Coppieters W, Docampo E, Georges M, Ajarchouh Z, Massart A, Racapé J, Abramowicz D, Abramowicz M.

Am J Transplant. 2017 Jan;17(1):201-209. doi: 10.1111/ajt.13912. Epub 2016 Jul 22.

30.

Donor Specific Antibodies are not only directed against HLA-DR: Minding your Ps and Qs.

Cross AR, Lion J, Loiseau P, Charron D, Taupin JL, Glotz D, Mooney N.

Hum Immunol. 2016 Nov;77(11):1092-1100. doi: 10.1016/j.humimm.2016.04.003. Epub 2016 Apr 6. Review.

PMID:
27060781
31.

Deciphering IgM interference in IgG anti-HLA antibody detection with flow beads assays.

Visentin J, Guidicelli G, Couzi L, Merville P, Lee JH, Di Primo C, Taupin JL.

Hum Immunol. 2016 Nov;77(11):1048-1054. doi: 10.1016/j.humimm.2016.02.008. Epub 2016 Feb 20.

PMID:
26902993
32.

Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Cluzeau T, Lambert J, Raus N, Dessaux K, Absi L, Delbos F, Devys A, De Matteis M, Dubois V, Filloux M, Fort M, Hau F, Jollet I, Labalette M, Masson D, Mercier B, Pedron B, Perrier P, Picard C, Quainon F, Ramounau-Pigot A, Renac V, Van Endert P, Charron D, Peffault de la Tour R, Taupin JL, Loiseau P.

Bone Marrow Transplant. 2016 May;51(5):687-91. doi: 10.1038/bmt.2015.351. Epub 2016 Feb 8.

PMID:
26855158
33.

Are complement-fixing antibodies against denatured HLA antigens clinically relevant?

Visentin J, Guidicelli G, Taupin JL.

Exp Mol Pathol. 2016 Jun;100(3):532-3. doi: 10.1016/j.yexmp.2016.01.008. Epub 2016 Jan 19. No abstract available.

PMID:
26801224
34.

Anti-HLA donor-specific antibodies are not created equally. Don't forget the flow….

Bachelet T, Visentin J, Guidicelli G, Merville P, Couzi L, Taupin JL.

Transpl Int. 2016 Apr;29(4):508-10. doi: 10.1111/tri.12745. Epub 2016 Feb 17. No abstract available.

35.

Calibration free concentration analysis by surface plasmon resonance in a capture mode.

Visentin J, Minder L, Lee JH, Taupin JL, Di Primo C.

Talanta. 2016 Feb 1;148:478-85. doi: 10.1016/j.talanta.2015.11.025. Epub 2015 Nov 10.

PMID:
26653475
36.

Use of Single-Antigen Flow Beads Assays to Assess Anti-HLA Donor-Specific Antibody Strength.

Loiseau P, Amokhrane K, Visentin J, Kheav VD, Caillat-Zucman S, Taupin JL.

Biol Blood Marrow Transplant. 2016 Feb;22(2):394-395. doi: 10.1016/j.bbmt.2015.11.006. Epub 2015 Nov 17. No abstract available.

37.

Evaluation of the iBeads assay as a tool for identifying class I HLA antibodies.

Visentin J, Guidicelli G, Nong T, Moreau JF, Merville P, Couzi L, Lee JH, Taupin JL.

Hum Immunol. 2015 Sep;76(9):651-6. doi: 10.1016/j.humimm.2015.09.012. Epub 2015 Sep 25.

PMID:
26407911
38.

Assessing HLA Antibody Strength: Have We Thought About Everything?

Visentin J, Guidicelli G, Taupin JL.

Am J Transplant. 2015 Dec;15(12):3271. doi: 10.1111/ajt.13452. Epub 2015 Sep 11. No abstract available.

39.

Evolution of serum and intra-graft donor-specific anti-HLA antibodies in a patient with two consecutive liver transplantations.

Neau-Cransac M, Le Bail B, Guidicelli G, Visentin J, Moreau K, Quinart A, Boueilh A, Laurent C, Taupin JL.

Transpl Immunol. 2015 Oct;33(2):58-62. doi: 10.1016/j.trim.2015.08.002. Epub 2015 Aug 28.

PMID:
26321506
40.

Deleterious Impact of Donor-Specific Anti-HLA Antibodies Toward HLA-Cw and HLA-DP in Kidney Transplantation.

Bachelet T, Martinez C, Del Bello A, Couzi L, Kejji S, Guidicelli G, Lepreux S, Visentin J, Congy-Jolivet N, Rostaing L, Taupin JL, Kamar N, Merville P.

Transplantation. 2016 Jan;100(1):159-66. doi: 10.1097/TP.0000000000000821.

PMID:
26262501
41.

Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.

Guidicelli G, Guerville F, Lepreux S, Wiebe C, Thaunat O, Dubois V, Visentin J, Bachelet T, Morelon E, Nickerson P, Merville P, Taupin JL, Couzi L.

J Am Soc Nephrol. 2016 Feb;27(2):615-25. doi: 10.1681/ASN.2014040326. Epub 2015 Jun 5.

42.

Deciphering allogeneic antibody response against native and denatured HLA epitopes in organ transplantation.

Visentin J, Guidicelli G, Moreau JF, Lee JH, Taupin JL.

Eur J Immunol. 2015 Jul;45(7):2111-21. doi: 10.1002/eji.201445340. Epub 2015 Apr 28.

43.

Intravenous immunoglobulins and rituximab therapy for severe transplant glomerulopathy in chronic antibody-mediated rejection: a pilot study.

Bachelet T, Nodimar C, Taupin JL, Lepreux S, Moreau K, Morel D, Guidicelli G, Couzi L, Merville P.

Clin Transplant. 2015 May;29(5):439-46. doi: 10.1111/ctr.12535. Epub 2015 Mar 30.

PMID:
25739833
44.

Clinical impact of preformed donor-specific denatured class I HLA antibodies after kidney transplantation.

Visentin J, Marroc M, Guidicelli G, Bachelet T, Nong T, Moreau JF, Lee JH, Merville P, Couzi L, Taupin JL.

Clin Transplant. 2015 May;29(5):393-402. doi: 10.1111/ctr.12529. Epub 2015 Mar 13.

PMID:
25683727
45.

Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation.

Visentin J, Guidicelli G, Bachelet T, Jacquelinet C, Audry B, Nong T, Dubois V, Moreau JF, Lee JH, Couzi L, Merville P, Taupin JL.

Transplantation. 2014 Oct 15;98(7):738-44. doi: 10.1097/TP.0000000000000229.

PMID:
25289917
46.

Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin pathway in human lymphocytes.

Noceti OM, Woillard JB, Boumediene A, Esperón P, Taupin JL, Gerona S, Valverde M, Touriño C, Marquet P.

Clin Chem. 2014 Oct;60(10):1336-45. doi: 10.1373/clinchem.2014.223511. Epub 2014 Aug 20.

47.

Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss.

Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, Scoazec JY, Bachelet T, Lepreux S, Visentin J, Merville P, Fremeaux-Bacchi V, Morelon E, Taupin JL, Dubois V, Thaunat O.

J Am Soc Nephrol. 2015 Feb;26(2):457-67. doi: 10.1681/ASN.2013101144. Epub 2014 Aug 14.

48.

Deciphering complement interference in anti-human leukocyte antigen antibody detection with flow beads assays.

Visentin J, Vigata M, Daburon S, Contin-Bordes C, Fremeaux-Bacchi V, Dromer C, Billes MA, Neau-Cransac M, Guidicelli G, Taupin JL.

Transplantation. 2014 Sep 27;98(6):625-31. doi: 10.1097/TP.0000000000000315.

PMID:
25058376
49.

Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.

Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M.

Clin Transplant. 2014 Sep;28(9):1054-60. doi: 10.1111/ctr.12418. Epub 2014 Aug 18.

PMID:
25040585
50.

Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

Papuchon J, Pinson P, Guidicelli GL, Bellecave P, Thomas R, LeBlanc R, Reigadas S, Taupin JL, Baril JG, Routy JP, Wainberg M, Fleury H; Provir/Latitude 45 study group.

PLoS One. 2014 Jun 25;9(6):e100452. doi: 10.1371/journal.pone.0100452. eCollection 2014.

Supplemental Content

Loading ...
Support Center